![](/img/cover-not-exists.png)
Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies
Aboud, Michael, Orkin, Chloe, Podzamczer, Daniel, Bogner, Johannes R, Baker, David, Khuong-Josses, Marie-Aude, Parks, David, Angelis, Konstantinos, Kahl, Lesley P, Blair, Elizabeth A, Adkison, KimberlLanguage:
english
Journal:
The Lancet HIV
DOI:
10.1016/S2352-3018(19)30149-3
Date:
July, 2019
File:
PDF, 1.91 MB
english, 2019